150
Participants
Start Date
July 31, 2005
Study Completion Date
October 31, 2007
Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan
FOLFOX 6
"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
FOLFIRI
"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
Institute of Oncology, Ljubljana
Univ. Klinik für Innere Medizin I, Vienna
National Medical Center, Budapest
"University Hospital Queen Joanna", Sofia
SBALO National Oncology Center, Sofia
Hospital Amadora Sintra, Servico de Oncologia, Amadora
Csolnoky Ferenc County Hospital, Veszprém
LKH Leoben, Abt. für Innere Medizin, Leoben
Charles University Prague, Dep. of Oncology, Prague
Markusovsy Hospital, Szomathely
Univ. Hospital Brno, Dept. Of Clinical Oncology, Brno
Institute of Oncology, Sarajevo
Hospital de Beja, Beja
National Cancer Institute, Bratislava
Institutul Oncologic Cluj, Cluj-Napoca
University Hospital for Tumors, Zagreb
University Hospital Rebro, Zagreb
Bank of Cyprus Oncology Center, Nicosia
Hadassah Medical Center, Jerusalem
Souraski Medical Center, Tel Aviv
Hospital San Teotóno -, Viseu
Institutul Oncologic Bucuresti, Bucharest
Ankara Hacettepe University, Oncology Unit, Ankara
Gazi University Medical Faculty, Ankara
9 Eyul University Medical Faculty, Dep of Oncology, Izmir
Hospital Distrital de Faro, Faro
Hospital Geral de Sto. António, Porto
Central European Cooperative Oncology Group
OTHER